Zalicus

CombinatoRx Reports Second Positive Phase 2 Study with CRx-102

CombinatoRx Reports Second Positive Phase 2 Study with CRx-102

May 22, 2006

Achieved Primary Endpoint with Statistically Significant Reduction in C-Reactive Protein in Human Inflammatory Model

Helicos BioSciences Corporation

Helicos BioSciences Announces First "Early Access" Partnership with Institute for Systems Biology

Helicos BioSciences Announces First "Early Access" Partnership with Institute for Systems Biology

June 7, 2006

CAMBRIDGE, Mass.--(BUSINESS WIRE)--June 7, 2006--Helicos BioSciences, a pioneer in high-speed, high-sensitivity sequencing, today announced a new partnership with the Institute for Systems Biology (ISB) as the company's first "Early Access" program research collaborator. The ISB is an internationally renowned non-profit research institute dedicated to the study and application of systems biology. The partnership will allow the ISB access to Helicos' True Single Molecule Sequencing (tSMS(TM)) technology and protocols for use in its scientifically groundbreaking research projects.

Morphotek, Inc.

Morphotek Announces Initiation of Phase II Clinical Studies For MORAb-003 in Ovarian Cancer

Morphotek Announces Initiation of Phase II Clinical Studies For MORAb-003 in Ovarian Cancer

June 8, 2006

EXTON, Pa., June 8 /PRNewswire/ -- Morphotek, Inc. today announced initiation of Phase II efficacy studies in major cancer centers worldwide for its anti-cancer antibody MORAb-003. MORAb-003 is a monoclonal antibody that targets the folate receptor alpha (FRA), a target over-expressed in over 90% of ovarian cancers and a number of other solid tumors. The antibody works via suppression of FRA-mediated signal transduction and induces tumor-specific cytotoxicity by both antibody dependent cellular and complement mediated immune-effector mechanisms.

Helicos BioSciences Corporation

Helicos BioSciences Names Steve Lombardi Senior Vice President of Marketing

Helicos BioSciences Names Steve Lombardi Senior Vice President of Marketing

June 14, 2006

6/14/2006 8:00:00 AM EST -- Helicos BioSciences, a pioneer in high-speed, high-sensitivity sequencing, today announced that it has named longtime biotechnology executive Steve Lombardi as Senior Vice President of Marketing.

Adnexus Therapeutics

Compound Therapeutics Becomes AdNexus Therapeutics

Compound Therapeutics Becomes AdNexus Therapeutics

June 21, 2006

Company Continues to Advance the AdNectin Therapeutic Class

Waltham, MA, June 21, 2006– Compound Therapeutics, Inc., a private biotechnology company focused on development of medicines based on AdNectins™, today announced it has changed its name to Adnexus Therapeutics, Inc.. The company’s new website will be www.adnexustx.com

Adnexus Therapeutics

First AdNectin Therapeutic, CT-322, Clears FDA IND Review to Start Clinical Trials

First AdNectin Therapeutic, CT-322, Clears FDA IND Review to Start Clinical Trials

June 21, 2006

Anti-Cancer Therapeutic is a First in a Broadly Applicable, Innovative Class of Targeted Therapeutics

Acceleron Pharma, Inc.

Acceleron Initiates Phase 1 Clinical Trial of ACE-011, a Novel Treatment for Bone Loss

Acceleron Initiates Phase 1 Clinical Trial of ACE-011, a Novel Treatment for Bone Loss

June 21, 2006

Acceleron Becomes a Clinical-Stage Company

Adnexus Therapeutics

Adnexus Therapeutics Closes $27M Series B Funding

Adnexus Therapeutics Closes $27M Series B Funding

June 26, 2006

Series B Financing Led by Venrock will Advance Breakthrough New Product Class, AdNectins

Selecta Biosciences, Inc.

Selecta Biosciences Appoints Werner Cautreels, Ph.D., as Company's First CEO

Selecta Biosciences Appoints Werner Cautreels, Ph.D., as Company's First CEO

August 16, 2010

Watertown, Massachusetts, USA, August 16, 2010 – Selecta Biosciences, Inc., a biopharmaceutical company developing synthetic nanoparticle vaccines and immunotherapies, announced today that Werner Cautreels, Ph.D. has been appointed as President and Chief Executive Officer. He has also been appointed to the company's Board of Directors. Dr.

Selecta Biosciences, Inc.

Selecta Biosciences Receives $3 Million from NIH/NIDA to Develop Nicotine Vaccine for Smoking Cessation

Selecta Biosciences Receives $3 Million from NIH/NIDA to Develop Nicotine Vaccine for Smoking Cessation

August 16, 2010

Targeted Synthetic Vaccine Particles (tSVP) Offer Potential for Increased Anti-Nicotine Efficacy to Increase Success of Smoking Cessation